Millennium Management LLC Has $934,000 Stake in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)

Millennium Management LLC raised its stake in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 282.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 141,951 shares of the company's stock after purchasing an additional 104,837 shares during the period. Millennium Management LLC owned 0.43% of Lexeo Therapeutics worth $934,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. Janus Henderson Group PLC increased its holdings in shares of Lexeo Therapeutics by 15.3% during the 4th quarter. Janus Henderson Group PLC now owns 4,339,254 shares of the company's stock worth $28,508,000 after buying an additional 576,059 shares during the last quarter. Deutsche Bank AG increased its stake in Lexeo Therapeutics by 172.8% during the fourth quarter. Deutsche Bank AG now owns 13,226 shares of the company's stock worth $87,000 after acquiring an additional 8,378 shares during the last quarter. DAFNA Capital Management LLC raised its holdings in shares of Lexeo Therapeutics by 56.9% in the 4th quarter. DAFNA Capital Management LLC now owns 393,083 shares of the company's stock worth $2,586,000 after purchasing an additional 142,500 shares during the period. Corton Capital Inc. acquired a new position in Lexeo Therapeutics during the fourth quarter valued at approximately $91,000. Finally, Bridgeway Capital Management LLC purchased a new stake in Lexeo Therapeutics during the 4th quarter worth $428,000. Hedge funds and other institutional investors own 60.67% of the company's stock.

Lexeo Therapeutics Stock Up 12.9%

Shares of LXEO stock traded up $0.50 on Monday, reaching $4.38. 870,657 shares of the company's stock traded hands, compared to its average volume of 516,560. The company has a market capitalization of $145.40 million, a P/E ratio of -1.39 and a beta of 0.52. Lexeo Therapeutics, Inc. has a 12-month low of $1.45 and a 12-month high of $19.50. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.95 and a current ratio of 5.95. The business's 50 day moving average price is $2.97 and its two-hundred day moving average price is $4.47.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.19). On average, equities analysts forecast that Lexeo Therapeutics, Inc. will post -3.14 earnings per share for the current year.

Analyst Ratings Changes

LXEO has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. lowered their price target on shares of Lexeo Therapeutics from $16.00 to $10.00 and set an "overweight" rating for the company in a report on Friday, May 30th. Chardan Capital cut their target price on Lexeo Therapeutics from $22.00 to $20.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th. HC Wainwright lowered their target price on Lexeo Therapeutics from $23.00 to $15.00 and set a "buy" rating on the stock in a research report on Friday, May 16th. Leerink Partners reduced their price target on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an "outperform" rating for the company in a research note on Monday, March 24th. Finally, Royal Bank of Canada lowered their price objective on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an "outperform" rating on the stock in a research note on Tuesday, March 25th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Lexeo Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $18.50.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.